Conference
New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.
Abstract
413
Background: Prognostic factors for overall survival (OS) have been identified in pts receiving post-platinum chemotherapy for advanced UC, but it is unknown whether these factors and/or others optimally predict OS for pts treated with PD1/PD-L1 inhibitor therapy. Methods: Pt level data from two UC salvage trials evaluating atezolizumab were used: IMvigor210 (n = 310) for training and PCD4989g (n = 95) for validation. …
Authors
Pond GR; Niegisch G; Rosenberg JE; Dreicer R; Powles T; Necchi A; Wei XX; Grivas P; Balar AV; Galsky MD
Volume
36
Pagination
pp. 413-413
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2018
DOI
10.1200/jco.2018.36.6_suppl.413
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X